Newamsterdam Pharma Company Nv (NAMS)

Shares of Newamsterdam Pharma Company (NAMS) dropped by 10.07% from $7.05 to $6.34 in the trading on Monday, October 23, 2023. The reason why NAMS stock down is due to a change in the management board. On Monday, Newamsterdam Pharma announced the appointment of Ian Somaiya as its Chief Financial Officer. Mr. Somaiya boasts over twenty-five years of experience in senior leadership roles within the biopharmaceutical industry. Notably, during his 20-year tenure on Wall Street, he gained recognition as a highly regarded industry equity analyst, conducting extensive research on over 100 biotechnology companies across various therapeutic areas, technology platforms, and development stages. His research earned him the distinction of Best on the Street by The Wall Street Journal for multiple consecutive years. Ian Somaiya holds a B.A. in Biology and Neuroscience from New York University. However, despite his impressive credentials, investors reacted cautiously to this news, leading to a decline in the stock's price.